(R)-Toluene-4-sulfonic acid 2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethyl ester | 364080-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-Toluene-4-sulfonic acid 2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethyl ester
• 英文别名: [(2R)-2-(6-chloropyridin-3-yl)-2-hydroxyethyl] 4-methylbenzenesulfonate
• CAS: 364080-72-8
• 化学式: C₁₄H₁₄ClNO₄S
• 分子量: 327.788
• InChiKey: WKLUYFLLUYRAAM-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-Toluene-4-sulfonic acid 2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethyl ester 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到2-chloro-5-[(2R)-2-oxiranyl]pyridine
  参考文献：
  名称：

  Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

  摘要：

  A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human beta(3)-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the beta(3)-AR, functional selectivity against beta(1)- and beta(2)-ARs, and favorable pharmacokinetic profiles in vivo. Compound 17 increased oxygen consumption in rats, a measure of energy expenditure, with an EDO20% of 2 mg/kg. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.072
• 作为产物：
  描述：

  (R)-1-(6-Chloro-,pyridin-3-yl)-ethane-1,2-diol 、 对甲苯磺酰氯 在 甲苯 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 ethyl acetate hexanes 作用下， 以 吡啶 为溶剂， 反应 2.33h， 以to afford 23.3 g of the title compound (I-2d) as colorless crystals的产率得到(R)-Toluene-4-sulfonic acid 2-(6-chloro-pyridin-3-yl)-2-hydroxy-ethyl ester
  参考文献：
  名称：

  β3 agonists and uses thereof

  摘要：

  本文描述了具有公式（I）的磺酰胺化合物，以及它们在治疗依赖于与β肾上腺素受体相关的信号通路的疾病中的应用，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力和心血管疾病。

  公开号：

  US06939867B2

文献信息

• Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
  申请人：Pfizer Products Inc.

  公开号：EP1236723A1

  公开（公告）日：2002-09-04

  Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases.

  公式（I）的磺胺化合物被描述，并且它们被用于治疗依赖于与β-肾上腺素受体相关的信号通路的疾病，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力以及心血管疾病。
• Beta3 agonists and uses thereof
  申请人：——

  公开号：US20020128247A1

  公开（公告）日：2002-09-12

  Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with &bgr;-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases. 1

  化学式为(I)的磺胺化合物被描述，并且它们在治疗依赖与β-肾上腺素受体相关的信号通路的疾病中的用途也被描述，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力和心血管疾病。
• Process for preparing substituted pyridnes
  申请人：Pfizer Inc

  公开号：US20040133005A1

  公开（公告）日：2004-07-08

  A process for preparing a compound of the formula 1 wherein n, R 1 , R 2 , R 3 and X are as defined above, used as an intermediate in the synthesis of &bgr;-adrenergic receptor agonists.

  一种制备化合物1的方法，其中n，R1，R2，R3和X的定义如上所述，该化合物用作合成β-肾上腺素受体激动剂的中间体。
• β3 agonists and uses thereof
  申请人：Dow Robert L.

  公开号：US06939867B2

  公开（公告）日：2005-09-06

  Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases

  本文描述了具有公式（I）的磺酰胺化合物，以及它们在治疗依赖于与β肾上腺素受体相关的信号通路的疾病中的应用，例如肥胖症、糖尿病、高血压、胃肠道低动力或高动力和心血管疾病。
• US6518431B2
  申请人：——

  公开号：US6518431B2

  公开（公告）日：2003-02-11